Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Achira is engaged in development and commercialization of PoC medical test kits in India
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Subscribe To Our Newsletter & Stay Updated
